

Healthcare Services


Quarterly Update | Q3 2020



Industry Overview

M&A Transactions & Performance





Source: Capital IQ. Data as of September 30, 2020

Above noted mid-market M&A activity includes disclosed transactions not exceeding a total transaction value of \$500 million. All figures are in CAD.

Canadian Transactions
51

Canadian Transaction Value \$555 million


(+8.3% vs. Q2 2020)

US Transaction Value \$7.9 billion

(+49.3% vs. Q2 2020)

US Transactions 375

Healthcare merger and acquisition (M&A) activity in the third quarter of 2020 exceeded \$8.4 billion in disclosed transaction value across 426 deals in Canada and the US. The average deal size among disclosed transactions was \$19.3 million. Grifols, S.A.'s purchase of Green Cross Biotherapeutics Inc. for \$213 million was the largest transaction of the quarter. In Canada, the top three subcategories for deal activity in the quarter were pharmaceuticals (17), healthcare services (7) and healthcare technology (6). Average EV/EBITDA multiples calculated for the last 12 months in 2020 for public companies have remained relatively flat with an average of 10.6x for the third quarter compared to 10.0x in the second quarter and 10.6x in the first quarter of 2020.



Select Recent M&A Transactions







Announced	Sept. 30, 2020
TEV	\$144 million
TEV/EBITDA	Not disclosed
Location (Vendor)	Niles, IL

- Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer pharmaceutical products in Japan and internationally.
- Alva-Amco Pharmacal Companies, Inc. manufactures specialty non-prescription pharmaceuticals, dietary supplements, and cosmetics.
- The transaction allows Kobayashi to enter the North American market.



acquired



Announced	Sept. 18, 2020
TEV	\$65 million
TEV/EBITDA	Not disclosed
Location	Cranbury, NJ

(Vendor)

- BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry
- SciSafe, Inc. provides storage services for pharmaceutical and biological samples.
- BioLife will pay \$15 million in cash and \$15 million in newly-issued shares of BioLife common stock, and SciSafe's shareholders are eligible over the next four years to receive up to 0.63 million additional shares based on revenue milestones.





Announced	Sept. 14, 2020
TEV	\$10 million
TEV/EBITDA	Not disclosed
Location (Vendor)	Toronto, ON

- Cloud Practice Inc. (a subsidiary of CloudMD) has entered into a binding term sheet to acquire 100% of iMD Health Global Corp. (iMD) from Apotex Pharmachem, Inc. and others.
- Consideration includes \$1.5 million in cash; \$4.5 million in shares of CloudMD; and performance-based earnouts of \$4 million.
- iMD's patient engagement and doctor education software will be immediately accretive to CloudMD.



Acquired minority stake in



Announced Sept. 8, 2020

TEV Not disclosed

TEV/EBITDA Not disclosed

Location (Vendor) Longueuil, QC

- Churchill Asset Management is a lender based out of New York City, NY, and caters to a wide array of industries such as private equity, asset management, insurance, pharmaceuticals, food, beverage, real estate, and others.
- Knowlton Development Corporation formulates and manufactures pharmacy front-store products and a range of lotions, creams, oils, gels, and ointments.

Industry Overview



Pharmacies and Drug Stores in Canada

The Pharmacy & Drug Store industry includes the retailing of prescription and over-the-counter medications, health and beauty items, toiletries, and consumable goods directly to consumers.

Industry Glance

2020 Revenue

\$46.7B

Annual Growth 2015 - 2020

3.9%


Projected Annual Growth 2020 - 2025

1.7%

Number of Businesses in 2020

6,620

Products and Services Segmentation (2020)



- Prescription pharmaceuticals
- Personal and beauty products
- Nonprescription pharmaceuticals
- Other home health products

Dentistry in Canada

The Dental industry captures establishments of licenced dentists engaged in private or group practice offering orthodontics, periodontics, surgery, prevention, and other products and services.

Industry Glance

2020 Revenue

\$16.2B

Annual Growth 2015 - 2020

1.3%


Projected Annual Growth 2020 – 2025

2.9%

Number of Businesses in 2020

26,572

Products and Services Segmentation (2020)





- Restorative
- Surgery
- Orthodontics
- Prevention
- Prosthodontics
- Other


Macroeconomic Indicators




The Healthcare industry is affected by a number of key macroeconomic industry growth drivers. Below, we highlight total public and private health expenditure, per capita disposable income, national unemployment rates, and the aging population in Canada. According to economic trend projections, Canada and the US will experience short-term volatility but figures are expected to improve starting in 2021, supporting the view of continuing industry stability and growth.










National Unemployment Rate

Public Comparable Analysis


Growth, Margins & Multiples




LTM Revenue Growth




NTM Revenue Growth




LTM EBITDA Margin




NTM EBITDA Margin



LTM EV/EBITDA




NTM EV/EBITDA



Public Comparable Analysis







Public Comparable Analysis





We have selected a group of publicly traded healthcare entities for this high-level analysis. These public companies help act as a proxy for the industry and provide strong industry context.

(Figures in CAD millions, except percentages and ratios)

(Figures in CAD millions, except Company	Market Capitalization	Enterprise Value	LTM Operating Figures			NTM Consensus Estimates			Valuation		
			Revenue	Revenue Growth	EBITDA	EBITDA Margin	Revenue Growth		NTM EV/EBITDA	LTM EV/EBITDA	LTM EV/REV
Retail Pharmacy											
CVS Health Corporation	\$101,829	\$201,648	\$357,719	16.3%	\$29,286	8.2%	0.4%	6.0%	9.2x	7.0x	0.6x
Rite Aid Corporation	\$676	\$9,449	\$30,405	7.6%	\$1,884	6.2%	4.0%	2.0%	14.0x	4.9x	0.3x
CareRx Corporation	\$101	\$165	\$134	12.6%	\$7	5.3%	43.3%	8.5%	10.6x	23.4x	1.2x
Median	\$676	\$9,449	\$30,405	12.6%	\$1,884	6.2%	4.0%	6.0%	10.6x	7.0x	0.6x
Mean	\$34,202	\$70,420	\$129,419	12.2%	\$10,392	6.6%	15.9%	5.5%	11.3x	11.8x	0.7x
Pharmaceuticals											
Johnson & Johnson	\$522,248	\$537,248	\$108,431	(1.0%)	\$36,562	33.7%	6.5%	34.2%	13.8x	14.8x	5.0x
Merck & Co., Inc.	\$279,528	\$305,992	\$63,083	3.0%	\$26,539	42.1%	5.0%	43.4%	11.3x	12.1x	4.9x
Pfizer Inc.	\$271,716	\$341,587	\$64,817	(8.3%)	\$25,853	39.9%	1.6%	46.3%	11.2x	12.7x	5.2x
Mylan N.V.	\$10,214	\$26,156	\$15,648	1.9%	\$4,774	30.5%	0.2%	30.3%	5.4x	5.6x	1.7x
Bausch Health Companies Inc.	\$7,349	\$38,704	\$11,030	(3.8%)	\$4,237	38.4%	0.4%	40.0%	8.7x	9.3x	3.6x
Median	\$271,716	\$305,992	\$63,083	(1.0%)	\$25,853	38.4%	1.6%	40.0%	11.2x	12.1x	4.9x
Mean	\$218,211	\$249,938	\$52,602	(1.6%)	\$19,593	36.9%	2.8%	38.8%	10.1x	10.9x	4.1x
Pharmaceutical Distributors											
Walgreens Boots Alliance, Inc.	\$41,471	\$96,887	\$182,199	2.0%	\$11,855	6.5%	3.8%	4.8%	10.7x	7.5x	0.5x
McKesson Corporation	\$32,183	\$43,464	\$314,220	6.2%	\$4,376	1.4%	2.4%	1.8%	7.6x	10.1x	0.1x
AmerisourceBergen Corporation	\$26,361	\$28,163	\$253,397	5.1%	\$3,258	1.3%	2.9%	1.3%	8.1x	8.8x	0.1x
Cardinal Health, Inc.	\$18,353	\$24,306	\$208,012	5.1%	\$3,867	1.9%	1.1%	1.7%	6.5x	6.4x	0.1x
Median	\$29,272	\$35,813	\$230,704	5.1%	\$4,122	1.6%	2.7%	1.8%	7.9x	8.2x	0.1x
Mean	\$29,592	\$48,205	\$239,457	4.6%	\$5,839	2.8%	2.6%	2.4%	8.2x	8.2x	0.2x
Healthcare Service Providers											
HCA Healthcare, Inc.	\$56,153	\$96,321	\$67,634	1.3%	\$14,013	20.7%	5.4%	19.3%	7.3x	7.3x	1.4x
Universal Health Services, Inc.	\$12,114	\$16,652	\$15,341	1.9%	\$2,494	16.3%	0.6%	15.3%	7.1x	6.8x	1.1x
Tenet Healthcare Corporation	\$3,442	\$23,194	\$23,357	(4.2%)	\$3,396	14.5%	7.2%	14.4%	6.4x	6.9x	1.0x
Community Health Systems, Inc.	\$647	\$17,690	\$16,425	(11.1%)	\$1,816	11.1%	(3.4%)	13.3%	8.3x	9.9x	1.1x
Median	\$7,778	\$20,442	\$19,891	(1.4%)	\$2,945	15.4%	3.0%	14.9%	7.2x	7.1x	1.1x
Mean	\$18,089	\$38,464	\$30,689	(3.0%)	\$5,430	15.6%	2.4%	15.6%	7.3x	7.7x	1.2x
Healthcare/Dental Equipment	: & Supplies										
Becton, Dickinson and Company	\$89,862	\$111,528	\$23,011	(1.1%)	\$6,394	27.8%	5.3%	29.7%	15.3x	17.8x	4.9x
Baxter International Inc.	\$54,242	\$58,273	\$15,520	3.1%	\$4,033	26.0%	0.1%	22.3%	16.7x	14.8x	3.8x
DENTSPLY SIRONA Inc.	\$12,730	\$14,299	\$4,677	(12.8%)	\$955	20.4%	1.6%	19.3%	15.6x	15.3x	3.1x
Henry Schein, Inc.	\$11,181	\$13,802	\$12,735	(3.6%)	\$1,179	9.3%	4.7%	8.2%	12.6x	12.0x	1.1x
Patterson Companies, Inc.	\$3,057	\$3,995	\$7,256	(2.9%)	\$463	6.4%	2.2%	4.9%	10.9x	8.7x	0.6x
Median	\$12,730	\$14,299	\$12,735	(2.9%)	\$1,179	20.4%	2.2%	19.3%	15.3x	14.8x	3.1x
Mean	\$34,214	\$40,379	\$12,640	(3.5%)	\$2,605	18.0%	2.8%	16.9%	14.2x	13.7x	2.7x

About Us



MNP Corporate Finance (MNPCF) has a dedicated team of over 50 merger, acquisition, and transaction professionals across Canada. MNPCF works with clients in virtually all industries as they prepare, plan and execute transactions.

Our typical transactions range in value between \$3 million and \$300 million.

Local and International Reach

MNP is a participating firm within Praxity, a unique global alliance of independent accounting/advisory firms created to answer global business needs. As a member of Praxity, we are able to offer access to corporate finance, accounting and tax advisory services worldwide. We are also affiliated with Corporate Finance Cross Border, which consists of 150+ M&A professionals in more than 25 countries.







Services

- Divestitures
- Acquisitions
- Debt Financing
- · Due Diligence
- Transaction Advisory Services

Recently Closed Deals (National)






















About Us



Deal Experience

Since our inception, our team has advised on hundreds of transactions, in a wide range of industries with diverse enterprise values. In the past five years alone we have completed over 120 transactions worth over \$2 billion (not including due diligence engagements).

Industry Experience

- Food & Beverage
- Retail & Distribution
- Manufacturing
- Agriculture
- · Automotive
- Materials
- · Health Care
- Pharmaceutical

- Transportation
- Construction
- Software
- Financial Services
- Technology
- Energy
- Oilfield Services
- Real Estate

Hands-on Approach

Current M&A transactions require a hands-on approach from start to finish including the active engagement of senior resources. Our senior resources are dedicated to our clients and are available as necessary and appropriate. We keep our clients regularly informed of the engagement status, issues we are encountering, successes, and overall progress.

Integrated Service Offering

We draw on the vast experience and deep specialist knowledge network of our partners locally, nationally and internationally as specialty issues arise, such as pre-transaction tax planning, transaction structuring, estate planning, valuation, due diligence, performance improvement, and risk management.

Recently Closed Deals (National)





















Leadership Team



Transaction Leadership



Brett Franklin President Brett.Franklin@mnp.ca 204.336.6190



Aleem Bandali Managing Director Aleem.Bandali@mnp.ca 778.374.2140



Dale Antonsen Managing Director Dale.Antonsen@mnp.ca 250.979.2578



Mike Reynolds Managing Director Mike.Reynolds@mnp.ca 587.702.5909



Mark Regehr Managing Director Mark.Regehr@mnp.ca 780.969.1404



Erik St-Hilaire Managing Director Erik.St-Hilaire@mnp.ca 204.336.6200



Stephen Shaw Managing Director Stephen.Shaw@mnp.ca 416.515.3883



Dan Porter Managing Director Dan.Porter@mnp.ca 416.515.3877



Kevin Tremblay Managing Director Kevin.Tremblay@mnp.ca 647.943.4051



Jon Edgett Managing Director Jon.Edgett@mnp.ca 519.772.7460



Patrick Khouzam Managing Director Patrick.Khouzam@mnp.ca 514.228.7874



Craig Maloney Managing Director Craig.Maloney@mnp.ca 902.493.5430

Due Diligence Leadership



Johnny Earl Managing Director Johnny.Earl@mnp.ca 604.637.1514



John Caggianiello Managing Director John.Caggianiello@mnp.ca 416.513.4177